{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4"},{"groupId":"OG001","value":"66.7"}]}],"title":"Requires less time in the clinic"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8"},{"groupId":"OG001","value":"57.8"}]}],"title":"Feels more comfortable during administration"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3"},{"groupId":"OG001","value":"42.2"}]}],"title":"Lower level of injection-site pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9"},{"groupId":"OG001","value":"20.0"}]}],"title":"Feels less emotionally distressing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"The PPQ is an instrument that has been developed from patient interviews and includes questions to evaluate directly from participants their preference regarding mode of administration, as well as the strength of the preference, and the reason for the preference. PPQ Question 3 evaluated 2 main reasons for participants' preference for one of the administration methods (SC or IV), with response options including \"feels less emotionally distressing\", \"requires less time in the clinic\", and \"lower level injection-site pain\". As pre-specified by the supplemental statistical analysis plan (sSAP), the most frequent reasons for preferring SC administration as assessed by PPQ Question 3 were reported among all participants preferring SC in each treatment arm. Treatment arms A (Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV) and B (Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC) were defined as treatment sequence arms in the protocol.","groups":[{"description":"In the Treatment Crossover Period participants first received pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles, followed by pembrolizumab IV for three 21-day cycles.","id":"OG000","title":"Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV"},{"description":"In the Treatment Crossover Period participants first received pembrolizumab IV for three 21-day cycles, followed by pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles.","id":"OG001","title":"Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC"}],"paramType":"NUMBER","populationDescription":"The analysis population included all randomized participants who received all three doses of pembrolizumab plus berahyaluronidase alfa SC and all three doses of pembrolizumab IV during the treatment crossover period, subsequently answered question 3 of the PPQ on Day 106, and preferred SC administration.","reportingStatus":"POSTED","timeFrame":"Day 106","title":"Percentage of Participants Who Preferred SC Administration According to Most Frequent Reasons of Preference As Assessed by PPQ Question 3","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}